AKT1 and neoplasm: In contrast, EGFR-TKIs like gefitinib, erlotinib, lapatinib, afatinib, and dacomitinib inhibit the intracellular tyrosine kinase domain of EGFR, thereby preventing downstream signaling pathways, such as PI3K/AKT and MAPK/ERK, which drive tumor proliferation and survival.